PL3037101T3 - Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu - Google Patents

Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Info

Publication number
PL3037101T3
PL3037101T3 PL14199709T PL14199709T PL3037101T3 PL 3037101 T3 PL3037101 T3 PL 3037101T3 PL 14199709 T PL14199709 T PL 14199709T PL 14199709 T PL14199709 T PL 14199709T PL 3037101 T3 PL3037101 T3 PL 3037101T3
Authority
PL
Poland
Prior art keywords
pregnancy
implantation
receptor antagonist
luteal phase
oxytocin receptor
Prior art date
Application number
PL14199709T
Other languages
English (en)
Inventor
Joan-Carles Arce
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52338895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3037101(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL3037101T3 publication Critical patent/PL3037101T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
PL14199709T 2014-12-22 2014-12-22 Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu PL3037101T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14199709.8A EP3037101B1 (en) 2014-12-22 2014-12-22 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Publications (1)

Publication Number Publication Date
PL3037101T3 true PL3037101T3 (pl) 2019-06-28

Family

ID=52338895

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14199709T PL3037101T3 (pl) 2014-12-22 2014-12-22 Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Country Status (21)

Country Link
US (4) US9579305B2 (pl)
EP (2) EP3501533B1 (pl)
JP (2) JP6858130B2 (pl)
KR (1) KR102715569B1 (pl)
CN (2) CN113940990A (pl)
AU (1) AU2015367900B2 (pl)
BR (1) BR112017013521A2 (pl)
CA (1) CA2971846A1 (pl)
CL (1) CL2017001640A1 (pl)
EA (1) EA201791361A1 (pl)
ES (2) ES3041573T3 (pl)
IL (1) IL253078B (pl)
MX (1) MX374877B (pl)
MY (1) MY181349A (pl)
PH (1) PH12017550030B1 (pl)
PL (1) PL3037101T3 (pl)
SG (1) SG11201705175RA (pl)
TW (1) TWI702043B (pl)
UA (1) UA125492C2 (pl)
WO (1) WO2016105190A1 (pl)
ZA (1) ZA201704958B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu
SG10202009723PA (en) 2016-01-04 2020-11-27 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2018015497A2 (en) * 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物
JP7837561B2 (ja) * 2020-10-28 2026-03-31 国立大学法人東海国立大学機構 悪性中皮腫の治療剤および悪性中皮腫患者の選択方法
CN114292907A (zh) * 2020-12-15 2022-04-08 苏州亿康医学检验有限公司 用于反复植入失败的生物标志物和诊断与治疗方法
CN117531006B (zh) * 2023-10-10 2025-02-11 山东奥克斯畜牧种业有限公司 一种提高牛胚胎移植受胎率的组合制剂及其制备方法与应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
AUPP421298A0 (en) 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
IL156729A0 (en) * 2001-01-09 2004-02-08 Schering Ag The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
DE60238490D1 (de) * 2001-09-12 2011-01-13 Merck Serono Sa Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke
DK1480998T3 (da) 2002-02-27 2007-03-26 Ferring Bv Mellemprodukter og fremgangsmåder til fremstilling af heptapeptidoxytocinanaloger
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
FR2849380A1 (fr) * 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7111275B2 (en) 2003-08-28 2006-09-19 International Business Machines Corporation Electronic circuit design analysis system
CA2539306A1 (en) 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
JP2007505888A (ja) 2003-09-22 2007-03-15 ファイザー インコーポレイテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
DE602006021736D1 (de) * 2005-05-10 2011-06-16 Ferring Bv Verwendung von antagonisten von oxytocin und/oder vasopressin bei der assistierten fortpflanzung
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
EP2430154A4 (en) 2009-05-14 2014-01-08 Adelaide Res & Innovation Pty METHOD FOR REMOVING AND RINSING OOCYTES
WO2013004612A1 (en) 2011-07-01 2013-01-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining developmental stage of human cumulus cells
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
EP2855694B1 (en) 2012-05-31 2018-12-26 Progyny, Inc. In vitro embryo blastocyst prediction methods
HK1213454A1 (zh) 2012-11-26 2016-07-08 Ferring B.V. 使用图像分析诊断子宫收缩水平的方法和系统
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Also Published As

Publication number Publication date
ES2716862T3 (es) 2019-06-17
TWI702043B (zh) 2020-08-21
TW201636016A (zh) 2016-10-16
US20170348325A1 (en) 2017-12-07
US10183029B2 (en) 2019-01-22
JP2021054863A (ja) 2021-04-08
US20170189415A1 (en) 2017-07-06
IL253078A0 (en) 2017-08-31
CA2971846A1 (en) 2016-06-30
CN107249618A (zh) 2017-10-13
UA125492C2 (uk) 2022-04-13
US20200352962A1 (en) 2020-11-12
EP3037101B1 (en) 2019-03-06
US11752157B2 (en) 2023-09-12
JP6858130B2 (ja) 2021-04-14
KR20170135821A (ko) 2017-12-08
US20160175283A1 (en) 2016-06-23
CN113940990A (zh) 2022-01-18
ES3041573T3 (en) 2025-11-13
JP2018505212A (ja) 2018-02-22
EP3501533B1 (en) 2025-07-09
MY181349A (en) 2020-12-21
EP3501533A1 (en) 2019-06-26
PH12017550030A1 (en) 2018-01-15
US9579305B2 (en) 2017-02-28
NZ733869A (en) 2020-10-30
EA201791361A1 (ru) 2017-11-30
AU2015367900A1 (en) 2017-08-03
IL253078B (en) 2020-04-30
WO2016105190A1 (en) 2016-06-30
AU2015367900B2 (en) 2021-05-13
US10688106B2 (en) 2020-06-23
PH12017550030B1 (en) 2024-07-03
CN107249618B (zh) 2021-11-16
SG11201705175RA (en) 2017-07-28
CL2017001640A1 (es) 2018-01-26
BR112017013521A2 (pt) 2018-03-06
ZA201704958B (en) 2019-10-30
MX2017008455A (es) 2018-04-26
EP3037101A1 (en) 2016-06-29
MX374877B (es) 2025-03-06
JP7184935B2 (ja) 2022-12-06
KR102715569B1 (ko) 2024-10-11

Similar Documents

Publication Publication Date Title
ZA201704958B (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
LT3498725T (lt) Steroidas su 19-nor c3,3-dipakeistuoju c21-n-pirazolilu, skirtas naudoti terapijoje
SG11201700770PA (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
IL251630A0 (en) Combined therapy for use in cancer treatment
GB201600635D0 (en) Anchor for inplantation in body tissue
PT3311168T (pt) Nova estrutura de tnf para utilização em terapia
PL3158057T3 (pl) Terapia komórkami macierzystymi w patologiach endometrium
ES3066097T3 (en) Microspheres for use in therapeutic embolization
GB201403969D0 (en) Compounds for use in controlling body fat
GB201702160D0 (en) Inhibitors for use in therapy
LT3057589T (lt) (s)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje
IL231278A0 (en) A system to assist a needy person in transitioning between standing and sitting and between sitting and standing
SG10202010711UA (en) Colloidal Particles for Use in Medicine
GB201615844D0 (en) Agents for use in therapy
PT3592184T (pt) Conjunto para utilização na preparação de uma bebida por meio de um dispositivo de preparação de bebidas
IL252043A0 (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders
PL3278941T3 (pl) Przyrząd do montażu na sucho płyt gipsowo-kartonowych
GB201617451D0 (en) Polypeptides for use in therapy
GB201516723D0 (en) Polypeptides for use in therapy
GB201416493D0 (en) Polypeptides for use in therapy
GB201707863D0 (en) Methods for improving mitophagy in subjects
GB201707861D0 (en) Methods for improving mitophagy in subjects
GB201706596D0 (en) Methods for improving mitophagy in subjects
GB201706594D0 (en) Methods for improving mitophagy in subjects
ZA201501073B (en) Device for improving resting comfort of a person in transit